NCT04239469View on ClinicalTrials.gov

Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.

PHASE2UnknownINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

June 15, 2020

Study Completion Date

September 15, 2020

Conditions

FibromyalgiaCannabis

Interventions

DRUG

KL16-012

Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD

DRUG

Placebo

Placebo

Sponsors

Lead Sponsor

Knop Laboratorios

All Listed Sponsors

lead

Knop Laboratorios

INDUSTRY